Policy Brief. 24 June 2022. This policy brief, one of two on the updated hepatitis C (HCV) guidelines, focuses on the new recommendations on simplified service delivery for a public health approach to HCV testing, care and treatment. These recommendations include decentralization, integration and ta...sk-sharing, in addition to the use of point-of-care (POC) HCV viral load assays and reflex viral load testing.
more
The response to a cholera outbreak must focus on limiting mortality and reducing the spread of the disease. It should be comprehensive and multisectoral, including epidemiology, case management, water, sanitation and hygiene, logistics, community engagement and risk communication. All efforts must b...e well coordinated to ensure a rapid and effective response across sectors.
This document provides a framework for detecting and monitoring cholera outbreaks and organizing the response. It also includes a short section linking outbreak response to both preparedness and long-term prevention activities.
more
Large size: Download directly from the website: https://www.washcluster.net/sites/gwc.com/files/2022-01/Unicef_Cholera%20Toolkit_2013.pdf
Policy Brief
November 2014
Accessed on 07.03.2023
A – Z of Rabies – A guide to the world´s deadliest disease
Mission Rabies
Review
S Afr Med J 2014;104(3):174-177. DOI: 10.7196/SAMJ.7968
Programmatic update
April 2012
Executive Summary
Lancet Infect Dis 2020 Published Online May 5, 2020 https://doi.org/10.1016/ S1473-3099(20)30254-1
Volume 2 · Supplement 4 · November 2016
ISSN 2055-66-40 – Print
Foreword
| ISSN 2055-66-59 – Online
www.viruseradication.com
This module introduces the “Vaccinator’s Manual”, a guideline for vaccinators. The aim of the manual is to update EPI guidelines to include all the changes since the third edition of the Vaccinators Manual (2008)
This guidance provides an overview of interventions to improve early diagnosis of TB and treatment completion in these populations, as well as factors to consider when developing programmes for health communication, awareness and education, and programme monitoring and evaluation
tep 1 Competencies have been designed to provide staff with the core skills required to care for a critically ill patient safely, whilst under supervision. It is expected that Step 1 competencies will be completed prior to commencing an academic critical care programme.
Steps 2 & 3 Competencies hav...e been designed to further develop your essential critical care skills and will require enhanced theoretical knowledge to underpin your practice. It is anticipated that Steps 2 & 3 competencies will be undertaken whilst undertaking an academic critical care programme.
Step 4 Competencies have been designed to provide staff with the core skills required to take charge in a critical care unit; building management and leadership capability into your professional development, to demonstrate safe and effective coordination and prioritisation of unit workload, workforce and resources.
You can downlaod any of the Steps Competency Documents from this link
more
Developed by the HHS Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission—
A Working Group of the Office of AIDS Research Advisory Council (OARAC)
Accessed: 12.02.2020
Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte...d with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.
more
PeerJ PrePrints , http://dx.doi.org/10.7287/peerj.preprints.579v1 2 Nov 2014